ClinicalTrials.gg
CompletedNCT05651542Updated Sep 28, 2026Results posted

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

An interventional study of Comprehensive Self-Management Intervention and Control in Inflammatory Bowel Diseases, Ulcerative Colitis and Crohn Disease, sponsored by University of Washington. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University of Washington · Not applicable, Interventional, and Other

How we know

Updated Sep 28, 2026Results postedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Enrollment
155th of 327
55 · median 50
Started
2023
with 18 others
No phase
131 of 463
35 open now
Registered
374th of 463
by date

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 155th largest by enrollment of the 327 interventional ones that give a count, is one of 19 that started in 2023, is one of 131 with no phase, and was the 374th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

This study aims to test the feasibility, acceptability, and preliminary efficacy of a comprehensive self-management (CSM) intervention for people with inflammatory bowel disease (IBD). The CSM-IBD intervention is an adaption of the CSM intervention initially developed for individuals with irritable bowel syndrome. The intervention has eight sessions which cover an introduction to IBD, symptom tracking, cognitive behavioral strategies, relaxation, sleep, diet, and pain management.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Ulcerative Colitis
  • Crohn Disease

Keywords

  • IBD
  • UC
  • CD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthcare provider diagnosis of inflammatory bowel disease
  • Report current symptoms
  • Able to read and write in English

Exclusion criteria

Exclusion Criteria:

  • Live outside of Washington state
  • Bowel-related surgery within the past month
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Comprehensive Self-Management

    The 8 week intervention is delivered online with a brief weekly check-in with a registered nurse.

    Behavioral: Comprehensive Self-Management Intervention

  • Other
    Usual care group

    The control group will receive standard care without the comprehensive self-management intervention.

    Other: Control

Interventions

  • BehavioralComprehensive Self-Management Intervention

    In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.

  • OtherControl

    The control group will receive standard care.

06

What researchers measure

Primary outcomes

  1. Recruitment Feasibility

    Percentage comprised of number of participants enrolled divided by the number of participants approached.

    Time frame: From screening to enrollment, an average of one month

  2. Intervention Feasibility

    Measured with the Feasibility of Intervention Measure (FIM) in which participants respond to four questions on a 5-point Likert scale from completely disagree (1) to completely agree (5). Range: 1 to 5. A higher score indicates greater feasibility.

    Time frame: 3 months

Secondary outcomes

  1. Change in Quality of Life

    Short Inflammatory Bowel Disease Questionnaire is a 10-item questionnaire which evaluates quality of life. Participants respond on a 7-item Likert scale from all the time to none of the time. Total score range: 10 to 70. A higher score indicates greater quality of life.

    Time frame: Baseline, 3 months, 6 months

  2. Change in Abdominal Pain Symptoms

    Abdominal pain was measured using a numeric rating scale where participants report the severity of the symptom from not present (0) to worst possible (10).

    Time frame: Baseline, 3 months, 6 months

Other outcomes

  1. Self-Efficacy for Managing Chronic Disease

    A 6-item self-report scale. Participants report ranging from not at all confident to totally confident. Range: 1-10. A higher score indicates greater self-efficacy

    Time frame: Baseline, 3 months, 6 months

  2. Index of Self-Regulation

    A 9-item scale to measure individual's level of self-regulation. Range: 0-36. A higher score indicates greater self-regulation.

    Time frame: Baseline, 3 months, 6 months

  3. Patient Activation Measure

    A 13-item scale which assess patient's beliefs, knowledge and confidence in managing their health. Range: 0-100. A higher score indicates greater activation.

    Time frame: Baseline, 3 months, 6 months

  4. Fecal Calprotectin

    Number of Participants with Inactive Disease based on fecal calprotectin (\<150 µg/g) assessed using ELISA.

    Time frame: Baseline, 3 months

07

Results

Posted Sep 28, 2026
Limitations and caveats
This study is a pilot study aimed at evaluating feasibility and acceptability

Participant flow

Participant flow — Overall Study
MilestoneComprehensive Self-ManagementUsual Care Group
Started3619
Completed2918
Not completed71

Outcome measures

PrimaryRecruitment Feasibility

Percentage comprised of number of participants enrolled divided by the number of participants approached.

Time frame:
From screening to enrollment, an average of one month
Reported as:
Count of participants · Participants
Recruitment Feasibility
ParticipantsAll Participants Approached
Recruitment Feasibility55
PrimaryIntervention Feasibility

Measured with the Feasibility of Intervention Measure (FIM) in which participants respond to four questions on a 5-point Likert scale from completely disagree (1) to completely agree (5). Range: 1 to 5. A higher score indicates greater feasibility.

Time frame:
3 months
Reported as:
Mean · Scores on a scale
Intervention Feasibility
Scores on a scaleComprehensive Self-Management
Intervention Feasibility4.34 ± 0.6
SecondaryChange in Quality of Life

Short Inflammatory Bowel Disease Questionnaire is a 10-item questionnaire which evaluates quality of life. Participants respond on a 7-item Likert scale from all the time to none of the time. Total score range: 10 to 70. A higher score indicates greater quality of life.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Mean · Score on a scale
Change in Quality of Life
Score on a scaleComprehensive Self-ManagementUsual Care Group
Baseline44.0 ± 9.646.4 ± 11.3
3 months post-randomization change score4.6 ± 9.41.6 ± 6.1
6 months post-randomization change score6.1 ± 8.21.7 ± 6.7
SecondaryChange in Abdominal Pain Symptoms

Abdominal pain was measured using a numeric rating scale where participants report the severity of the symptom from not present (0) to worst possible (10).

Time frame:
Baseline, 3 months, 6 months
Reported as:
Mean · Units on a scale
Change in Abdominal Pain Symptoms
Units on a scaleComprehensive Self-ManagementUsual Care Group
Baseline3.6 ± 2.24.2 ± 2.2
3 months post-randomization change score0.1 ± 2.3-0.8 ± 1.5
6 months post-randomization change score-0.4 ± 2.5-0.3 ± 1.8
Other pre-specifiedSelf-Efficacy for Managing Chronic Disease

A 6-item self-report scale. Participants report ranging from not at all confident to totally confident. Range: 1-10. A higher score indicates greater self-efficacy

Time frame:
Baseline, 3 months, 6 months
Reported as:
Mean · Score on a scale
Self-Efficacy for Managing Chronic Disease
Score on a scaleComprehensive Self-ManagementUsual Care Group
Baseline5.9 ± 1.95.6 ± 2.2
3 months post-randomization change score0.6 ± 1.80.5 ± 1.4
6 months post-randomization change score1.4 ± 2.30.4 ± 1.6
Other pre-specifiedIndex of Self-Regulation

A 9-item scale to measure individual's level of self-regulation. Range: 0-36. A higher score indicates greater self-regulation.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Mean · Score on a scale
Index of Self-Regulation
Score on a scaleComprehensive Self-ManagementUsual Care Group
Baseline23.0 ± 5.623.9 ± 3.4
3 months post-randomization change score4.7 ± 6.40.3 ± 4.1
6 months post-randomization change score4.9 ± 5.51.0 ± 4.5
Other pre-specifiedPatient Activation Measure

A 13-item scale which assess patient's beliefs, knowledge and confidence in managing their health. Range: 0-100. A higher score indicates greater activation.

Time frame:
Baseline, 3 months, 6 months
Reported as:
Mean · Score on a scale
Patient Activation Measure
Score on a scaleComprehensive Self-ManagementUsual Care Group
Baseline58.5 ± 13.762.0 ± 9.9
3 months post-randomization change score10.3 ± 14.62.6 ± 10.9
6 months post-randomization change score14.4 ± 13.34.3 ± 12.5
Other pre-specifiedFecal Calprotectin

Number of Participants with Inactive Disease based on fecal calprotectin (\<150 µg/g) assessed using ELISA.

Time frame:
Baseline, 3 months
Reported as:
Number · Participants
Fecal Calprotectin
ParticipantsComprehensive Self-ManagementUsual Care Group
Baseline2816
3 months post-randomization2013

Adverse events

Collected over from enrollment until the end of follow up, an average of 7 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Comprehensive Self-Management0/36 (0%)0/36 (0%)0/36 (0%)
Usual Care Group0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Comprehensive Self-ManagementUsual Care GroupTotal
Mean40.9 ± 12.335.3 ± 12.139.0 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Comprehensive Self-ManagementUsual Care GroupTotal
Female281644
Male8311
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Comprehensive Self-ManagementUsual Care GroupTotal
American Indian or Alaska Native314
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American134
White281139
More than one race224
Unknown or Not Reported112
Quality of Life
Quality of Life(Scores on a scale)Comprehensive Self-ManagementUsual Care GroupTotal
Mean44.0 ± 9.646.4 ± 11.344.8 ± 10.2
08

Study locations

1 site
  • University of Washington
    Seattle, Washington 98195, United States
09

References and documents

Publications

  • Tiles-Sar N, Neuser J, de Sordi D, Baltes A, Preiss JC, Moser G, Timmer A. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2025 Apr 17;4(4):CD006913. doi: 10.1002/14651858.CD006913.pub3. PubMed 40243391 ↗
  • Kamp K, Clark-Snustad K, Yoo L, Winders S, Cain K, Levy RL, Dey N, Lee S, Keefer L, Heitkemper M. A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2023 Jun 7;12:e46307. doi: 10.2196/46307. PubMed 37285195 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Sep 2025, 30 months.

Results were first posted in Sep 2026, 11 months after primary completion.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 30 months is above that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 15, 2022
StartActual
Mar 14, 2023
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Results first posted
Sep 28, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 28, 2026
Primary outcomes
2 edited, 1 removed
What changed in the outcomes
  • EditedRecruitment feasibilityFeasibilityTime frame: From screening to enrollment → From screening to enrollment, an average of one month
  • EditedIntervention feasibilityFeasibilityTime frame: 3 months
  • RemovedAcceptabilityTime frame: 6 months
Sep 28, 2026
Secondary outcomes
1 edited, 1 removed, 5 description edited
What changed in the outcomes
  • EditedChange in Abdominal Pain SymptomsTime frame: Baseline, 3 months, 6 months
  • DescriptionChange in Quality of Life: how it is measured was reworded
  • Removedother outcomeGut MicrobiomeTime frame: Baseline, 3 months
  • Descriptionother outcomeFecal Calprotectin: how it is measured was reworded
  • Descriptionother outcomeIndex of Self-Regulation: how it is measured was reworded
  • Descriptionother outcomePatient Activation Measure: how it is measured was reworded
  • Descriptionother outcomeSelf-Efficacy for Managing Chronic Disease: how it is measured was reworded
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Results posted
    Primary outcomes 2 edited, 1 removed
    What changed in the outcomes
    • EditedRecruitment feasibilityFeasibilityTime frame: From screening to enrollment → From screening to enrollment, an average of one month
    • EditedIntervention feasibilityFeasibilityTime frame: 3 months
    • RemovedAcceptabilityTime frame: 6 months
    Secondary outcomes 1 edited, 1 removed, 5 description edited
    What changed in the outcomes
    • EditedChange in Abdominal Pain SymptomsTime frame: Baseline, 3 months, 6 months
    • DescriptionChange in Quality of Life: how it is measured was reworded
    • Removedother outcomeGut MicrobiomeTime frame: Baseline, 3 months
    • Descriptionother outcomeFecal Calprotectin: how it is measured was reworded
    • Descriptionother outcomeIndex of Self-Regulation: how it is measured was reworded
    • Descriptionother outcomePatient Activation Measure: how it is measured was reworded
    • Descriptionother outcomeSelf-Efficacy for Managing Chronic Disease: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05651542
Responsible party
Kendra Kamp (Assistant Professor, Biobehavioral Nursing & Health Informatics, University of Washington) — Principal investigator
First posted
Dec 15, 2022
Start date
Mar 14, 2023
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Results posted
Sep 28, 2026
Last update
Sep 28, 2026

Study contacts

Kendra Kamp, PHD, RN
principal investigator · University of Washington

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion